You just read:

Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer

News provided by

Eli Lilly and Company

Oct 10, 2017, 06:45 ET